CEFOTAXIME SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Cefotaxime Sodium patents expire, and when can generic versions of Cefotaxime Sodium launch?
Cefotaxime Sodium is a drug marketed by Aurobindo Pharma, Aurobindo Pharma Ltd, Cephazone Pharma, Hospira, Hospira Inc, Lupin, and Wockhardt. and is included in nine NDAs.
The generic ingredient in CEFOTAXIME SODIUM is cefotaxime sodium. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cefotaxime sodium profile page.
Summary for CEFOTAXIME SODIUM
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 126 |
Clinical Trials: | 8 |
Patent Applications: | 2,845 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CEFOTAXIME SODIUM at DailyMed |
Recent Clinical Trials for CEFOTAXIME SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fayoum University Hospital | Phase 4 |
Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
Federal University of São Paulo | Phase 4 |